BG Medicine (BGMD) engages in the discovery, development, and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The company went public on February 4th 2011, at $7 a share. The stock has been under pressure since that time due to lackluster sales for their FDA/European approved manual Galectin-3 test. Delays with garnering FDA/European approval for their CardioSCORE test has also not helped. However, just recently BG Medicine saw a welcome reprieve for patient shareholders when they obtained the CE Mark for CardioSCORE Test in Europe, which sent its shares up to a 3 month high of $4.48 before retreating. If the large volume is any indication, many investors are watching the stock now, and so they should be. Here's an excerpt from their latest 10-Q filed on November 13th:

"New Commercial Strategy
On November 13, 2012, we